235 related articles for article (PubMed ID: 16328001)
21. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
22. Combination chemotherapy studies with gemcitabine.
van Moorsel CJ; Veerman G; Bergman AM; Guechev A; Vermorken JB; Postmus PE; Peters GJ
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-17-S7-23. PubMed ID: 9194475
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
van Moorsel CJ; Kroep JR; Pinedo HM; Veerman G; Voorn DA; Postmus PE; Vermorken JB; van Groeningen CJ; van der Vijgh WJ; Peters GJ
Ann Oncol; 1999 Apr; 10(4):441-8. PubMed ID: 10370787
[TBL] [Abstract][Full Text] [Related]
25. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
[TBL] [Abstract][Full Text] [Related]
26. Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.
Ruiz van Haperen VW; Veerman G; Eriksson S; Boven E; Stegmann AP; Hermsen M; Vermorken JB; Pinedo HM; Peters GJ
Cancer Res; 1994 Aug; 54(15):4138-43. PubMed ID: 8033147
[TBL] [Abstract][Full Text] [Related]
27. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma.
Rose PG
Int J Gynecol Cancer; 2005; 15 Suppl 1():18-22. PubMed ID: 15839954
[TBL] [Abstract][Full Text] [Related]
29. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
van Haperen VW; Veerman G; Vermorken JB; Pinedo HM; Peters G
Biochem Pharmacol; 1996 Apr; 51(7):911-8. PubMed ID: 8651941
[TBL] [Abstract][Full Text] [Related]
30. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB
Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396
[TBL] [Abstract][Full Text] [Related]
31. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Ruiz van Haperen VW; Veerman G; Boven E; Noordhuis P; Vermorken JB; Peters GJ
Biochem Pharmacol; 1994 Oct; 48(7):1327-39. PubMed ID: 7945430
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of thymidylate synthase by 2',2'-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine.
Honeywell RJ; Ruiz van Haperen VW; Veerman G; Smid K; Peters GJ
Int J Biochem Cell Biol; 2015 Mar; 60():73-81. PubMed ID: 25562513
[TBL] [Abstract][Full Text] [Related]
33. 2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines.
Ruiz van Haperen VW; Veerman G; Vermorken JB; Peters GJ
Biochem Pharmacol; 1993 Aug; 46(4):762-6. PubMed ID: 8363650
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro.
Dempke WC; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Hill BT
Carcinogenesis; 1992 Jul; 13(7):1209-15. PubMed ID: 1638688
[TBL] [Abstract][Full Text] [Related]
35. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
van Moorsel CJ; Bergman AM; Veerman G; Voorn DA; Ruiz van Haperen VW; Kroep JR; Pinedo HM; Peters GJ
Biochim Biophys Acta; 2000 Mar; 1474(1):5-12. PubMed ID: 10699484
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.
Hettinga JV; Lemstra W; Meijer C; Dam WA; Uges DR; Konings AW; De Vries EG; Kampinga HH
Br J Cancer; 1997; 75(12):1735-43. PubMed ID: 9192975
[TBL] [Abstract][Full Text] [Related]
38. The formation and repair of cisplatin-DNA adducts in wild-type and cisplatin-resistant L1210 cells: comparison of immunocytochemical determination with detection in isolated DNA.
Blommaert FA; Floot BG; van Dijk-Knijnenburg HC; Berends F; Baan RA; Schornagel JH; den Engelse L; Fichtinger-Schepman AM
Chem Biol Interact; 1998 Jan; 108(3):209-25. PubMed ID: 9528691
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic.
Bookman MA
Int J Gynecol Cancer; 2005; 15 Suppl 1():12-7. PubMed ID: 15839953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
